Review



cd10 antibody  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd10 antibody
    ABOs support efficient B cell development from HSPCs (A) Schematic overview of the ABO culture system. (B) Schematic overview of B cell development from HSPCs. (A and B) Created using BioRender (BioRender.com/9tddlci). (C) Flow cytometric plots showing CD33 + myeloid and <t>CD10</t> + lymphoid populations at day 35. (D) Quantification of CD33 + cell frequencies at days 21–35. (E and F) PCA illustrating the developmental trajectory of HSPCs in ABOs over time (E) and annotated with corresponding B cell stages (F). (G) Wanderlust trajectory depicting the dynamic expression of key markers during B cell development. (CLP, common lymphoid progenitors; IC, intracellular). (H) Two-dimensional flow cytometric plots showing marker expression along the Wanderlust trajectory. (I and J) Quantification of IgM + immature (I) and IgM + IgD + transitional B cells (J), shown as frequencies and output per input HSPC at days 21–35. (D, I, J) Statistical analysis was performed using two-way ANOVA with Tukey’s multiple-comparison test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (C–J) Results represent n = 3 individual donors in independent cultures. See also .
    Cd10 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/CD10+Antibody%2C+anti-human%2C+REAfinity/pmc13400188-5-0-7
    Average 92 stars, based on 13 article reviews
    cd10 antibody - by Bioz Stars, 2026-11
    92/100 stars

    Images

    1) Product Images from "ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development"

    Article Title: ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development

    Journal: Cell Reports Medicine

    doi: 10.1016/j.xcrm.2026.102879

    ABOs support efficient B cell development from HSPCs (A) Schematic overview of the ABO culture system. (B) Schematic overview of B cell development from HSPCs. (A and B) Created using BioRender (BioRender.com/9tddlci). (C) Flow cytometric plots showing CD33 + myeloid and CD10 + lymphoid populations at day 35. (D) Quantification of CD33 + cell frequencies at days 21–35. (E and F) PCA illustrating the developmental trajectory of HSPCs in ABOs over time (E) and annotated with corresponding B cell stages (F). (G) Wanderlust trajectory depicting the dynamic expression of key markers during B cell development. (CLP, common lymphoid progenitors; IC, intracellular). (H) Two-dimensional flow cytometric plots showing marker expression along the Wanderlust trajectory. (I and J) Quantification of IgM + immature (I) and IgM + IgD + transitional B cells (J), shown as frequencies and output per input HSPC at days 21–35. (D, I, J) Statistical analysis was performed using two-way ANOVA with Tukey’s multiple-comparison test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (C–J) Results represent n = 3 individual donors in independent cultures. See also .
    Figure Legend Snippet: ABOs support efficient B cell development from HSPCs (A) Schematic overview of the ABO culture system. (B) Schematic overview of B cell development from HSPCs. (A and B) Created using BioRender (BioRender.com/9tddlci). (C) Flow cytometric plots showing CD33 + myeloid and CD10 + lymphoid populations at day 35. (D) Quantification of CD33 + cell frequencies at days 21–35. (E and F) PCA illustrating the developmental trajectory of HSPCs in ABOs over time (E) and annotated with corresponding B cell stages (F). (G) Wanderlust trajectory depicting the dynamic expression of key markers during B cell development. (CLP, common lymphoid progenitors; IC, intracellular). (H) Two-dimensional flow cytometric plots showing marker expression along the Wanderlust trajectory. (I and J) Quantification of IgM + immature (I) and IgM + IgD + transitional B cells (J), shown as frequencies and output per input HSPC at days 21–35. (D, I, J) Statistical analysis was performed using two-way ANOVA with Tukey’s multiple-comparison test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (C–J) Results represent n = 3 individual donors in independent cultures. See also .

    Techniques Used: Expressing, Marker, Comparison

    B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed progenitor cells (A) Flow cytometric analysis of CD34, c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .
    Figure Legend Snippet: B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed progenitor cells (A) Flow cytometric analysis of CD34, c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .

    Techniques Used: Expressing

    RAG1 gene correction restores functional B-lymphopoiesis in RAG1-deficient mPB-derived HSPCs (A) Schematic overview of coRAG1 LV correction and subsequent ABO culture of HSPCs derived from patients with RAG1-SCID. Created using BioRender (BioRender.com/qo00iis). (B and C) Flow cytometric analysis of B cell commitment as assessed by CD10 and CD38 expression (B) and B-lineage progression (C) of healthy control UCB- and mPB-derived HSPCs in day 35 (UCB) and day 42 (mPB) ABOs, respectively. (D) Flow cytometric analysis of day 42 ABOs using healthy control and RAG1-deficient mPB HSPCs (UT, untransduced; T, transduced). (E) Quantification of the frequencies of intracellular (IC) IgM + , IgM + , and IgM + IgD + cells in day 42 ABOs (UT, untransduced; T, transduced). (F) Visualization of V H -J H rearrangements across conserved framework regions (FR1-3) of the IGHV locus by GeneScan analysis from healthy control (top), untransduced (UT; middle), and coRAG1-transduced (T; bottom) RAG1-deficient mPB HSPCs differentiated toward B cells in day 42 ABOs. (G) Flow cytometric analysis of CD40-stimulated ABO-CD19 + cells from control and transduced (T) RAG1-deficient mPB HSPCs on day 11. (H) Distribution of IgM + and Ig class-switched cells at day 11 post-stimulation of ABO-CD19 + cells using RAG1-deficient mPB HSPCs. (I) Quantification of antibody secretion over 24 h in culture supernatants collected from day 10–11 cultures (ND, not detected). (B, C, E, H) Statistical analysis was performed using unpaired Student’s t test (B), one-way ANOVA with Dunnett’s multiple-comparison test (E), or two-way ANOVA with Bonferroni’s multiple comparison test (C, H) (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (B, C) Data represent n = 3 (UCB) and n = 4 (mPB) HSPC-derived ABOs. (D–I) Data represent n = 4 healthy control mPB and n = 3 RAG1-SCID-patient-derived mPB samples in independent cultures. See also and .
    Figure Legend Snippet: RAG1 gene correction restores functional B-lymphopoiesis in RAG1-deficient mPB-derived HSPCs (A) Schematic overview of coRAG1 LV correction and subsequent ABO culture of HSPCs derived from patients with RAG1-SCID. Created using BioRender (BioRender.com/qo00iis). (B and C) Flow cytometric analysis of B cell commitment as assessed by CD10 and CD38 expression (B) and B-lineage progression (C) of healthy control UCB- and mPB-derived HSPCs in day 35 (UCB) and day 42 (mPB) ABOs, respectively. (D) Flow cytometric analysis of day 42 ABOs using healthy control and RAG1-deficient mPB HSPCs (UT, untransduced; T, transduced). (E) Quantification of the frequencies of intracellular (IC) IgM + , IgM + , and IgM + IgD + cells in day 42 ABOs (UT, untransduced; T, transduced). (F) Visualization of V H -J H rearrangements across conserved framework regions (FR1-3) of the IGHV locus by GeneScan analysis from healthy control (top), untransduced (UT; middle), and coRAG1-transduced (T; bottom) RAG1-deficient mPB HSPCs differentiated toward B cells in day 42 ABOs. (G) Flow cytometric analysis of CD40-stimulated ABO-CD19 + cells from control and transduced (T) RAG1-deficient mPB HSPCs on day 11. (H) Distribution of IgM + and Ig class-switched cells at day 11 post-stimulation of ABO-CD19 + cells using RAG1-deficient mPB HSPCs. (I) Quantification of antibody secretion over 24 h in culture supernatants collected from day 10–11 cultures (ND, not detected). (B, C, E, H) Statistical analysis was performed using unpaired Student’s t test (B), one-way ANOVA with Dunnett’s multiple-comparison test (E), or two-way ANOVA with Bonferroni’s multiple comparison test (C, H) (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (B, C) Data represent n = 3 (UCB) and n = 4 (mPB) HSPC-derived ABOs. (D–I) Data represent n = 4 healthy control mPB and n = 3 RAG1-SCID-patient-derived mPB samples in independent cultures. See also and .

    Techniques Used: Functional Assay, Derivative Assay, Expressing, Control, Comparison

    Related Articles

    other:

    Article Title: A bioprinted and scalable model of human tubulo-interstitial kidney fibrosis.
    Article Snippet: For the isolation of tubular epithelial cells, the prepared cell suspension from the kidney sample was incubated with CD10-Microbeads (Miltenyi biotec # 130-093-452) and isolated using MACS.

    Article Title: Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging
    Article Snippet: CD10 , REAL318 , 50 , 130-118-368 , FITC , Miltenyi Biotec.

    Article Title: Glomerulus on a chip to recapitulate glomerular filtration barrier
    Article Snippet: Sorted GEC are immediately frozen at 600,000 live cells/vial in Cryostor (Sigma Aldrich, #C2874-100ML).

    Article Title: Generation of a conditional cellular senescence model using proximal tubule cells and fibroblasts from human kidneys.
    Article Snippet: To isolate PT cells, a single-cell suspension was prepared as described above, incubated with CD10-Microbeads (Miltenyi Biotec, #130-093-452), and separated using MACS technology (Miltenyi Biotec, autoMACS Pro Separator, #130-092-545, autoMACS Columns #130-021-101).

    Purification:

    Article Title: Long Circulating RNAs Packaged in Extracellular Vesicles: Prospects for Improved Risk Assessment in Childhood B-Cell Acute Lymphoblastic Leukemia
    Article Snippet: .. They were purified from fresh human cord blood by positive selection using CD10 + and CD19 + magnetic microbeads (Miltenyi Biotec, Gaithersburg, MD, USA) [ ]. ..

    Article Title: Long Circulating RNAs Packaged in Extracellular Vesicles: Prospects for Improved Risk Assessment in Childhood B-Cell Acute Lymphoblastic Leukemia.
    Article Snippet: .. They were purified from fresh human cord blood by positive selection using CD10+ and CD19+ magnetic microbeads (Miltenyi Biotec, Gaithersburg, MD, USA) [8]. ..

    Selection:

    Article Title: Long Circulating RNAs Packaged in Extracellular Vesicles: Prospects for Improved Risk Assessment in Childhood B-Cell Acute Lymphoblastic Leukemia
    Article Snippet: .. They were purified from fresh human cord blood by positive selection using CD10 + and CD19 + magnetic microbeads (Miltenyi Biotec, Gaithersburg, MD, USA) [ ]. ..

    Article Title: Long Circulating RNAs Packaged in Extracellular Vesicles: Prospects for Improved Risk Assessment in Childhood B-Cell Acute Lymphoblastic Leukemia.
    Article Snippet: .. They were purified from fresh human cord blood by positive selection using CD10+ and CD19+ magnetic microbeads (Miltenyi Biotec, Gaithersburg, MD, USA) [8]. ..

    Flow Cytometry:

    Article Title: Recruitment of plasma cells from IL-21-dependent and IL-21-independent immune reactions to the bone marrow
    Article Snippet: .. Flow cytometry anti-human antibodies: CD3, clone BW264/56, VioBlue, Miltenyi Biotec, Cat. 130-113-133; CD3, clone UCHT1, FITC, DRFZ in-house; CD3, clone UCHT1, BUV395, BD Biosciences, Cat. 563546; CD3, clone HIT3a, PerCP, BioLegend, Cat. 300326; CD4, clone 91d6, Alexa Fluor 700, own conjugate; CD10, clone 97C5, VioBlue, Miltenyi Biotec, Cat. 130-099-670; CD14, clone TÜK4, VioBlue, Miltenyi Biotec, Cat. 130-113-152; CD14, clone M5E2, BUV395, BD Biosciences, Cat. 740286; CD19, clone SJ25C1, BV711, BD Biosciences, Cat. 563038; CD20, clone 2H7, BV510, BioLegend, Cat. 302340; CD27, clone MT271, PE, Miltenyi Biotec, Cat. 130-113-630; CD27, clone O323, APCCy7, BioLegend, Cat. 302816; CD27, clone O323, Brilliant Violet 421, BioLegend, Cat. 302824; CD27, clone L128, BV786, BD Biosciences, Cat. 563328; CD38, clone HIT2, APC, BioLegend, Cat. 303510; CD38, clone HIT2, APC-Cy7, BioLegend, Cat. 303534; CD38, clone HIT2, PerCP-Cy5.5, BioLegend, Cat. 551400; CD38, clone OKT10, Alexa Fluor 647, own conjugate; CD45RA, clone 4G11, FITC, own conjugate; CD56, clone HCD56, BV421, BioLegend, Cat. 318328; CD138, clone 44F9, PE, Miltenyi Biotec, Cat. 130-119-840; CD138, clone MI15, BUV737, BD Biosciences, Cat. 564393; CXCR5 , clone J252D4, Brilliant Violet 421, BioLegend, Cat. 356920; HLA-DR, clone Tü36, PE, BD Biosciences, Cat. 555561; IgA, clone G20-359, Biotin, BD Biosciences, Cat. 555884; IgA, Polyclonal, FITC, Southern Biotech, Cat. 2052-02; IgD, clone IA6-2, PE/ Dazzle594, BioLegend, Cat. 348240; IgD, clone IA6-2, APC-Cy7, BioLegend, Cat. 348218; IgG, clone G18-145, PE-Cy7, BD Biosciences, Cat. 561298; IgG, Polyclonal, Alexa647, Southern Biotech, Cat. 2014-31; IgM, clone G20-127, BV421, BD Biosciences, Cat. 562618; PD-1, clone EH12.2H7, Biotin/Streptavidin-PE-Cy7 BioLegend 329934. .. ELISA detection anti-human antibodies: IgA, Polyclonal, Biotin, Southern Biotech, Cat. 2050-08; IgG, Polyclonal, HRP, Southern Biotech, Cat. 2040-05; IgG, Polyclonal, HRP, Cytiva, Cat. NA933-1ML.

    Expressing:

    Article Title: Glomerulus on a chip to recapitulate glomerular filtration barrier
    Article Snippet: 3.8 Quality Control After selection, seed 10,000 cell per well of an 8-well chamber slide (Fisher Scientific #08-774-26) for further QC testing. .. 1st Isolate for CD10: After washing the sample, the anti-FITC multiSort Kit (Miltenyi, cat. 130-058-701) is used to select cells for CD10 expression first using anti-FITC beads (included in the kit). ..



    Similar Products

    cd10 antibody  (Miltenyi Biotec)
    92
    Miltenyi Biotec cd10 antibody
    ABOs support efficient B cell development from HSPCs (A) Schematic overview of the ABO culture system. (B) Schematic overview of B cell development from HSPCs. (A and B) Created using BioRender (BioRender.com/9tddlci). (C) Flow cytometric plots showing CD33 + myeloid and <t>CD10</t> + lymphoid populations at day 35. (D) Quantification of CD33 + cell frequencies at days 21–35. (E and F) PCA illustrating the developmental trajectory of HSPCs in ABOs over time (E) and annotated with corresponding B cell stages (F). (G) Wanderlust trajectory depicting the dynamic expression of key markers during B cell development. (CLP, common lymphoid progenitors; IC, intracellular). (H) Two-dimensional flow cytometric plots showing marker expression along the Wanderlust trajectory. (I and J) Quantification of IgM + immature (I) and IgM + IgD + transitional B cells (J), shown as frequencies and output per input HSPC at days 21–35. (D, I, J) Statistical analysis was performed using two-way ANOVA with Tukey’s multiple-comparison test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (C–J) Results represent n = 3 individual donors in independent cultures. See also .
    Cd10 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/CD10+Antibody%2C+anti-human%2C+REAfinity/pmc13400188-5-0-7
    Average 92 stars, based on 1 article reviews
    cd10 antibody - by Bioz Stars, 2026-11
    92/100 stars
    		  Buy from Supplier
    rabbit anti human cd10  (Bioss)
    92
    Bioss rabbit anti human cd10
    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers <t>(CD10,</t> CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.
    Rabbit Anti Human Cd10, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/CD10+Polyclonal+Antibody/pmc13121313-108-1-4
    Average 92 stars, based on 1 article reviews
    rabbit anti human cd10 - by Bioz Stars, 2026-11
    92/100 stars
    		  Buy from Supplier
    cd10  (Novocastra)
    86
    Novocastra cd10
    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers <t>(CD10,</t> CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.
    Cd10, supplied by Novocastra, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/anti+cd10/pm42301308-31-16-19
    Average 86 stars, based on 1 article reviews
    cd10 - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    cd10  (Nichirei Biosciences)
    86
    Nichirei Biosciences cd10
    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers <t>(CD10,</t> CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.
    Cd10, supplied by Nichirei Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/anti+cd10/pm42174107-62-68-71
    Average 86 stars, based on 1 article reviews
    cd10 - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    cd10  (Proteintech)
    93
    Proteintech cd10
    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers <t>(CD10,</t> CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.
    Cd10, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/MME%2CCD10+Antibody/pmc13019499-258-13-16
    Average 93 stars, based on 1 article reviews
    cd10 - by Bioz Stars, 2026-11
    93/100 stars
    		  Buy from Supplier
    cd10 inhibitor comprises uk 414 495  (Pfizer Inc)
    86
    Pfizer Inc cd10 inhibitor comprises uk 414 495
    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers <t>(CD10,</t> CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.
    Cd10 Inhibitor Comprises Uk 414 495, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/414+495+cd10+comprises+inhibitor+uk/us12594321-3515-4-8
    Average 86 stars, based on 1 article reviews
    cd10 inhibitor comprises uk 414 495 - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    cd10 inhibitor comprises omapatrilat bristol myers squibb  (Bristol Myers)
    86
    Bristol Myers cd10 inhibitor comprises omapatrilat bristol myers squibb
    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers <t>(CD10,</t> CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.
    Cd10 Inhibitor Comprises Omapatrilat Bristol Myers Squibb, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/bristol+cd10+comprises+inhibitor+myers+omapatrilat+squibb/us12594321-3511-4-8
    Average 86 stars, based on 1 article reviews
    cd10 inhibitor comprises omapatrilat bristol myers squibb - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    cd10 inhibitor comprises sacubitril  (Novartis)
    86
    Novartis cd10 inhibitor comprises sacubitril
    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers <t>(CD10,</t> CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.
    Cd10 Inhibitor Comprises Sacubitril, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/cd10+comprises+inhibitor+sacubitril/us12594321-3506-4-9
    Average 86 stars, based on 1 article reviews
    cd10 inhibitor comprises sacubitril - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier
    cd10 inhibitor comprises valsartan sacubritril  (Novartis)
    86
    Novartis cd10 inhibitor comprises valsartan sacubritril
    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers <t>(CD10,</t> CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.
    Cd10 Inhibitor Comprises Valsartan Sacubritril, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd10/cd10+comprises+inhibitor+sacubitril/us12594321-3508-4-9
    Average 86 stars, based on 1 article reviews
    cd10 inhibitor comprises valsartan sacubritril - by Bioz Stars, 2026-11
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    ABOs support efficient B cell development from HSPCs (A) Schematic overview of the ABO culture system. (B) Schematic overview of B cell development from HSPCs. (A and B) Created using BioRender (BioRender.com/9tddlci). (C) Flow cytometric plots showing CD33 + myeloid and CD10 + lymphoid populations at day 35. (D) Quantification of CD33 + cell frequencies at days 21–35. (E and F) PCA illustrating the developmental trajectory of HSPCs in ABOs over time (E) and annotated with corresponding B cell stages (F). (G) Wanderlust trajectory depicting the dynamic expression of key markers during B cell development. (CLP, common lymphoid progenitors; IC, intracellular). (H) Two-dimensional flow cytometric plots showing marker expression along the Wanderlust trajectory. (I and J) Quantification of IgM + immature (I) and IgM + IgD + transitional B cells (J), shown as frequencies and output per input HSPC at days 21–35. (D, I, J) Statistical analysis was performed using two-way ANOVA with Tukey’s multiple-comparison test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (C–J) Results represent n = 3 individual donors in independent cultures. See also .

    Journal: Cell Reports Medicine

    Article Title: ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development

    doi: 10.1016/j.xcrm.2026.102879

    Figure Lengend Snippet: ABOs support efficient B cell development from HSPCs (A) Schematic overview of the ABO culture system. (B) Schematic overview of B cell development from HSPCs. (A and B) Created using BioRender (BioRender.com/9tddlci). (C) Flow cytometric plots showing CD33 + myeloid and CD10 + lymphoid populations at day 35. (D) Quantification of CD33 + cell frequencies at days 21–35. (E and F) PCA illustrating the developmental trajectory of HSPCs in ABOs over time (E) and annotated with corresponding B cell stages (F). (G) Wanderlust trajectory depicting the dynamic expression of key markers during B cell development. (CLP, common lymphoid progenitors; IC, intracellular). (H) Two-dimensional flow cytometric plots showing marker expression along the Wanderlust trajectory. (I and J) Quantification of IgM + immature (I) and IgM + IgD + transitional B cells (J), shown as frequencies and output per input HSPC at days 21–35. (D, I, J) Statistical analysis was performed using two-way ANOVA with Tukey’s multiple-comparison test (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (C–J) Results represent n = 3 individual donors in independent cultures. See also .

    Article Snippet: CD10 Antibody, anti-human, REAfinity Biotin (REA877) , Miltenyi Biotec , Cat#130-114-500; RRID: AB_2726670.

    Techniques: Expressing, Marker, Comparison

    B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed progenitor cells (A) Flow cytometric analysis of CD34, c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .

    Journal: Cell Reports Medicine

    Article Title: ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development

    doi: 10.1016/j.xcrm.2026.102879

    Figure Lengend Snippet: B cell development in ABOs is not driven by expansion of pre-existing B-lineage-committed progenitor cells (A) Flow cytometric analysis of CD34, c-KIT (CD117), CD38, and CD10 expression on HSPCs before (top) and after depletion of Lin + CD10 + cells (bottom) by MACS, visualized with opt-SNE. (B and C) Flow cytometric analysis comparing the frequencies of CD33 + myeloid-committed (B) and CD10 + CD38 + lymphoid-committed cells (C) in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (D) Quantification of CD33 + and CD10 + CD38 + cells in day 35 ABOs. (E) Flow cytometric analysis comparing IgM + IgD − (immature) and IgM + IgD + (transitional) B cell frequencies in day 35 ABOs using bulk or Lin + CD10 + -depleted CD34 + HSPCs. (F) Quantification of IgM + and IgM + IgD + B cell frequencies in day 35 ABOs. (G) Distribution of HSPCs along the B cell developmental trajectory in day 35 ABOs. (D, F, G) Data are presented as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by Bonferroni’s multiple comparisons test (ns; non-significant). (A–G) Data represent n = 3 individual donors in independent cultures. See also .

    Article Snippet: CD10 Antibody, anti-human, REAfinity Biotin (REA877) , Miltenyi Biotec , Cat#130-114-500; RRID: AB_2726670.

    Techniques: Expressing

    RAG1 gene correction restores functional B-lymphopoiesis in RAG1-deficient mPB-derived HSPCs (A) Schematic overview of coRAG1 LV correction and subsequent ABO culture of HSPCs derived from patients with RAG1-SCID. Created using BioRender (BioRender.com/qo00iis). (B and C) Flow cytometric analysis of B cell commitment as assessed by CD10 and CD38 expression (B) and B-lineage progression (C) of healthy control UCB- and mPB-derived HSPCs in day 35 (UCB) and day 42 (mPB) ABOs, respectively. (D) Flow cytometric analysis of day 42 ABOs using healthy control and RAG1-deficient mPB HSPCs (UT, untransduced; T, transduced). (E) Quantification of the frequencies of intracellular (IC) IgM + , IgM + , and IgM + IgD + cells in day 42 ABOs (UT, untransduced; T, transduced). (F) Visualization of V H -J H rearrangements across conserved framework regions (FR1-3) of the IGHV locus by GeneScan analysis from healthy control (top), untransduced (UT; middle), and coRAG1-transduced (T; bottom) RAG1-deficient mPB HSPCs differentiated toward B cells in day 42 ABOs. (G) Flow cytometric analysis of CD40-stimulated ABO-CD19 + cells from control and transduced (T) RAG1-deficient mPB HSPCs on day 11. (H) Distribution of IgM + and Ig class-switched cells at day 11 post-stimulation of ABO-CD19 + cells using RAG1-deficient mPB HSPCs. (I) Quantification of antibody secretion over 24 h in culture supernatants collected from day 10–11 cultures (ND, not detected). (B, C, E, H) Statistical analysis was performed using unpaired Student’s t test (B), one-way ANOVA with Dunnett’s multiple-comparison test (E), or two-way ANOVA with Bonferroni’s multiple comparison test (C, H) (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (B, C) Data represent n = 3 (UCB) and n = 4 (mPB) HSPC-derived ABOs. (D–I) Data represent n = 4 healthy control mPB and n = 3 RAG1-SCID-patient-derived mPB samples in independent cultures. See also and .

    Journal: Cell Reports Medicine

    Article Title: ABO: A 3D stroma-supported culture platform enabling full human B-lymphopoiesis for disease modeling and gene therapy development

    doi: 10.1016/j.xcrm.2026.102879

    Figure Lengend Snippet: RAG1 gene correction restores functional B-lymphopoiesis in RAG1-deficient mPB-derived HSPCs (A) Schematic overview of coRAG1 LV correction and subsequent ABO culture of HSPCs derived from patients with RAG1-SCID. Created using BioRender (BioRender.com/qo00iis). (B and C) Flow cytometric analysis of B cell commitment as assessed by CD10 and CD38 expression (B) and B-lineage progression (C) of healthy control UCB- and mPB-derived HSPCs in day 35 (UCB) and day 42 (mPB) ABOs, respectively. (D) Flow cytometric analysis of day 42 ABOs using healthy control and RAG1-deficient mPB HSPCs (UT, untransduced; T, transduced). (E) Quantification of the frequencies of intracellular (IC) IgM + , IgM + , and IgM + IgD + cells in day 42 ABOs (UT, untransduced; T, transduced). (F) Visualization of V H -J H rearrangements across conserved framework regions (FR1-3) of the IGHV locus by GeneScan analysis from healthy control (top), untransduced (UT; middle), and coRAG1-transduced (T; bottom) RAG1-deficient mPB HSPCs differentiated toward B cells in day 42 ABOs. (G) Flow cytometric analysis of CD40-stimulated ABO-CD19 + cells from control and transduced (T) RAG1-deficient mPB HSPCs on day 11. (H) Distribution of IgM + and Ig class-switched cells at day 11 post-stimulation of ABO-CD19 + cells using RAG1-deficient mPB HSPCs. (I) Quantification of antibody secretion over 24 h in culture supernatants collected from day 10–11 cultures (ND, not detected). (B, C, E, H) Statistical analysis was performed using unpaired Student’s t test (B), one-way ANOVA with Dunnett’s multiple-comparison test (E), or two-way ANOVA with Bonferroni’s multiple comparison test (C, H) (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗∗ p < 0.0001). Data are presented as mean ± SEM. (B, C) Data represent n = 3 (UCB) and n = 4 (mPB) HSPC-derived ABOs. (D–I) Data represent n = 4 healthy control mPB and n = 3 RAG1-SCID-patient-derived mPB samples in independent cultures. See also and .

    Article Snippet: CD10 Antibody, anti-human, REAfinity Biotin (REA877) , Miltenyi Biotec , Cat#130-114-500; RRID: AB_2726670.

    Techniques: Functional Assay, Derivative Assay, Expressing, Control, Comparison

    3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers (CD10, CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Standalone methacrylated extracellular matrix for digital light processing bioprinting: a practical workflow

    doi: 10.3389/fbioe.2026.1774476

    Figure Lengend Snippet: 3D bioprinted dECM-MA bioink supports high-density parenchymal cell attachment, and early ECM remodeling. Human uterine stromal fibroblast cells (primary parenchymal cells of the uterine tissue, FC-0076 Lifeline Cell Technologies) were cultured in commercial media, exhibiting characteristic spindle-shaped stromal morphology (A) . These cells were immunofluorescently characterized for positive uterine and stromal markers (CD10, CD73, and Vimentin, respectively). CD31 isotype staining served as a negative control. Following expansion, cells were seeded at high density onto 3D bioprinted dECM-MA scaffolds, cultured for 16 h, and characterized by HR-SEM (B) . An overview SEM image shows a visibly high cell density on the ECM-MA after culture. Higher magnifications reveal a high-density (yellow rectangle, zoomed in) and lower density (blue rectangle, zoomed in) areas where human uterine stromal cells (yellow arrow) interact with the dECM-MA fibers (green arrow), suggesting biological interaction and constructive remodeling.

    Article Snippet: Specifically, rabbit anti-human CD10 (Bioss, Cat. No. BS-0527R-20; RID: AB_10854297) and rabbit anti-human vimentin (Bioss, Cat. No. BS-0756R-20; RRID: AB_10855343) were used as primary antibodies, with a rabbit IgG isotype control (Santa Cruz Biotechnology, Cat. No. sc-8306; RRID: AB_653100).

    Techniques: Cell Attachment Assay, Cell Culture, Staining, Negative Control